Shock Exchange | TalkMarkets | Page 1

Shock Exchange

Contributor's Links: New York Shock Exchange
B.A. in economics and MBA from top 10 business school. I have over 10 years of M&A / corporate finance experience. Currently head the New York Shock Exchange, a youth mentorship program that teaches investment management skills and competitive ...more
Following: 6 Followers: 2616

All Contributions

Latest Posts
1 to 16 of 148 Posts
1 2 3 ... 10 >>>
Lululemon's Valuation Appears Untenable
Tuesday, June 23, 2020 12:36 PM EDT
At over 40x EBITDA, the valuation appears untenable and it may be time to sell LULU.
In this article: LULU
Read
Facebook Cuts Third-Party Data Providers From Ad Targeting
Monday, April 2, 2018 9:54 AM EDT
FB is expected to cut third-party data providers from ad targeting. Such data providers may be forced to sell data to advertisers separate from FB. More companies chase the same ad dollars could hurt FB revenue.
In this article: META Also: EXPGY, ACXM
Read
Will Rihanna Tete-A-Tete Crush Snap?
Monday, April 2, 2018 7:41 AM EDT
Snap and Rihanna had tete-a-tete over an ad making light of domestic violence. Racy ads likely connotes Snap's desperate need to amplify user engagement to grow revenue.
In this article: SNAP Also: META
Read
Did Cambridge Analytica Debacle Kill Facebook's Business Model?
Friday, March 30, 2018 11:55 AM EDT
The Cambridge Analytica debacle has caused FB shares to fall by double digits. The dust-up could hurt consumer or advertiser sentiment.
In this article: META Also: CRZBF
Read
Micron Is Sitting In The Catbird Seat
Thursday, March 22, 2018 1:45 PM EDT
MU reports quarterly earnings after-hours. Top line revenue growth has been gaudy. The company is poised to exploit out-sized growth in memory for eSports and cloud computing.
In this article: MU Also: ORCL, MSFT, CRM
Read
5 Doctors Charged For Fentanyl Kickbacks; Is Insys At Risk?
Tuesday, March 20, 2018 6:03 AM EDT
Five doctors were charged for writing fentanyl prescriptions in exchange for kickbacks. One doctor was sentenced to four years in prison after admitting he took kickbacks from INSY. Is INSY at risk?
In this article: INSY Also: TEVA, AGN, MNK
Read
Oracle: It's All About The Cloud
Monday, March 19, 2018 12:42 PM EDT
ORCL reports quarterly earnings after-hours. Analysts expect revenue of $9.78 billion and eps of $0.72. The revenue estimate implies about 2% growth sequentially.
In this article: ORCL Also: SPY, AMZN
Read
Urban Outfitters Is Running In Quicksand
Monday, March 19, 2018 6:55 AM EDT
URBN's revenue is rising, operating expenses are outpacing revenue gains. As more sales come from via the digital channel it could stymie margins. Digital is growing but comparable store sales are in decline.
In this article: URBN Also: ANF, TGT, LULU
Read
Insys: Will The Drug Pipeline Drive Growth?
Monday, March 12, 2018 5:11 AM EDT
INSY's Q4 revenue declined over 40% Y/Y, but was up 3% sequentially. Revenue declines appear to have subsided. Its $163MM of cash and investments could support the company until its drug pipeline kicks in.
In this article: INSY Also: INVVY, ALKS
Read
Urban Outfitters: All About Guidance
Tuesday, March 6, 2018 2:09 PM EDT
URBN has been on a tear. The company had delivered strong revenue growth without sacrificing much in margins. Whether management can give strong guidance will determine if URBN falls hard or not.
In this article: URBN Also: LULU, SPY
Read
Mallinckrodt: Acthar, Deteriorating Credit Metrics Are Concerning
Wednesday, February 28, 2018 9:53 AM EDT
MNK produced a Q4 revenue beat, yet revenue still fell 5% Y/Y. Acthar revenue was off 9% Y/Y. This is a cause for concern. Debt/EBITDA rose to 4.8x. It could deteriorate further after the Sucampo deal.
In this article: MNK
Read
Can Valeant Bulls Stomach Double-Digit Revenue Declines?
Monday, February 26, 2018 7:17 AM EDT
Can VRX bulls stomach double-digit revenue declines? Asset sales have helped pare debt and reduce corporate overhead. Asset sales could be halted for the moment. If LOE exceeds revenue from new products then VRX's credit metrics could deteriorate.
In this article: VRX Also: PSHZF
Read
3 Key Takeaways From The Fed Minutes
Monday, February 26, 2018 6:41 AM EDT
The Fed minutes from January affirmed a gradual approach to rate hikes. The Fed wants a sustained return to 2% inflation. If the Fed remains data dependent it might not hike rates at all this year. This could be good for stocks short-term.
In this article: DIA, SPY
Read
Allergan: Europe Halts Esmya Prescriptions Amid Liver Risk Probe
Friday, February 23, 2018 10:34 AM EDT
The European Medicines Agency advised that no new patients take Esmya due to potential links to liver injury. The decision could stymie AGN's attempt to seek FDA approval for Esmya in the U.S.
In this article: AGN Also: GEDRY, GEDSF
Read
Wage Growth Stokes Inflation Fears
Sunday, February 18, 2018 6:01 PM EDT
In January the U.S. economy added 200,000 jobs, exceeding the 180,000 experts were expecting. Wage growth of 2.9% was the fastest since 2009. It sent financial markets lower on inflationary expectations.
In this article: DIA
Read
Valeant: Generic Syprine Is Here
Sunday, February 18, 2018 1:37 PM EDT
Teva announced the launch of generic Syprine, which treats Wilson's disease. Valeant's Syprine and Cuprimine have combined quarterly revenue and of $38MM. Hits to Syprine and Cuprimine could hurt sentiment for Valeant.
In this article: VRX, TEVA
Read
1 to 16 of 148 Posts
1 2 3 ... 10 >>>